Clinical Trial

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

Study acronym: PROTECTAA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-08; most recent amendment 2024-12-02.
Status change: Not Yet Recruiting → Recruiting 2024-04-24
Trial Details
NCT Number NCT06304857
Lead Sponsor 4th Military Clinical Hospital with Polyclinic, Poland
Conditions Breast Cancer, Heart Failure
Enrollment 188 participants
Start Date 2024-04-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-04